Relevant Biomarkers in Medical Practices: An Analysis of the Needs Addressed by an International Survey

• Published in: Journal of personalized medicine Vol. 12; no. 1; p. 106
• Main Authors: Abensur Vuillaume, Laure, Leichle, Thierry, Le Borgne, Pierrick, Grajoszex, Mathieu, Goetz, Christophe, Voss, Paul L, Ougazzaden, Abdallah, Salvestrini, Jean-Paul, d'Ortho, Marie-Pia
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 14-01-2022; MDPI
• Subjects: Biomarkers; Biosensors; Blood; Brain natriuretic peptide; C-reactive protein; Calcium-binding protein; Creatinine; Emergency medical care; Engineering Sciences; Family physicians; Life Sciences; Medical referrals; Pain; Pandemics; Patients; Physicians; Precision medicine; Questionnaires; Severe acute respiratory syndrome coronavirus 2; Troponin; France; United States > US; emergency overcrowding; biomarkers; biosensors
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm12010106

(1) Backround: Technological advances should foster gains in physicians' efficiency. For example, a reduction of the medical decision time can be enabled by faster biological tests. The main objective of this study was to collect responses from an international panel of physicians on their needs for biomarkers and also to convey the improvement in the outcome to be made possible by the potential development of fast diagnostic tests for these biomarkers. (2) Methods: we distributed a questionnaire on the Internet to physicians. (3) Results: 508 physicians participated in this survey. The mean age was 38 years. General practice and emergency medicine were heavily represented, with 95% CIs of 44% (39.78, 48.41) and 32% (27.84, 35.94)), respectively. The two most represented countries were France (95% CI: 74% (70.20, 77.83)) and the USA (95% CI: 11% (8.65, 14.18)). Ninety-eight percentages of the physicians thought that obtaining cited biomarkers more quickly would be beneficial to their practice and to patient's care. The main biomarkers of interest identified by our panel were troponin (95% CI: 51% (46.24, 54.94)), C-reactive protein (95% CI: 42% (38.03, 46.62)), D-dimer (95% CI: 29% (24.80, 32.68)), and brain natriuretic peptide (95% CI: 13% (10.25, 16.13)). (4) Conclusions: Our study highlights the real technological need for fast biomarker results, which could be provided by biosensors. The relevance of some answers such as troponin is questionable.